Medications used for obesity treatment such as cannabinoid receptor 1 (CB1) antagonist Rimonabant with side effects of either depression or gastrointestinal reactions, respectively (7), resulting in low patient compliance. The gene discussed is CNR1; the disease is major depressive disorder.